BMS Makes The Case For A Lasting Hematology Legacy

ASH Meeting Will Highlight Key Growth Products

Bristol became a major hematology player through its acquisition of Celgene and it has a multi-pronged plan for maintaining its position as generics approach for Revlimid and other key products.

Red Blood Cells and T-Cells floating through blood vessels 3d rendering
Bristol's hematology product revenue jumped from $2.5bn in 2019 to $18.1bn in 2020 after it bought Celgene • Source: Alamy

Bristol Myers Squibb Company gained a nearly $16bn hematology franchise through its acquisition of Celgene Corporation in late 2019, but three-fourths of that new revenue will start to disappear next year as generic versions of top-selling drug Revlimid (lenalidomide) begin to launch in 2022. However, BMS has a plan to maintain and build upon its hematology legacy and will unveil data underlying some elements of that strategy during the 11-14 December American Society of Hematology (ASH) meeting.

Bristol’s hematology drug sales totaled $18.13bn in 2020 – including $2.14bn from Sprycel (dasatinib) and $381m from Empliciti (elotuzumab), the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By 

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

PureTech Ponders Way Forward As CEO Exits

 
• By 

Bharatt Chowrira departs days after firm’s chair stepped down.

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

More from R&D